Clinical Trials Browser

Phase 1/2 × Withdrawn × Small Cell Lung Carcinoma × Clear all

NCT07328490 2026-04-28

Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer

Phase 1/2 Withdrawn

Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT04841538 2022-04-29

A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors

Phase 1/2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Thoracic Neoplasms, Small Cell Lung Carcinoma

NCT04543916 2021-03-03

Venetoclax and Irinotecan in Relapsed/Refractory SCLC

Phase 1/2 Withdrawn

Small Cell Lung Carcinoma

NCT02030184 2019-10-17

Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas

Phase 1/2 Withdrawn

EndocrineNETThoracic

Lung Neoplasms, Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT00769990 2017-12-13

Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases

Phase 1/2 Withdrawn

BreastDermatologicGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Pain, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT02661100 2016-12-07

A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients

Phase 1/2 Withdrawn

DermatologicOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Mesothelioma, Neoplasms, Small Cell Lung Carcinoma